Novel Drug Combo Doubles Progression-Free Survival in HER2-Negative Metastatic Breast Cancer
Ibrance plus Faslodex improved progression-free survival in certain patients with metastatic breast cancer, compared with those who continued to receive an aromatase inhibitor.
Drug Duo Boosts Outcomes in Elderly Patients With CLL
Fixed-duration Venclexta plus Gazyva produced longer remissions than chemoimmunotherapy in elderly patients with chronic lymphocytic leukemia and other comorbidities.
Novel Tyrosine Kinase Inhibitor Shows Promise for Metastatic Non-Small Cell Lung Cancer With Specific Genetic Mutation
Mobocertinib showed clinically meaningful benefits in patients with EGFR exon 20 insertion–positive metastatic non-small cell lung cancer with a manageable safety profile.
Brukinsa May Cause Fewer Side Effects Than Other BTK Inhibitors for Patients with B-Cell Malignancies
A clinical trial of Brukinsa (zanubrutinib) is open to patients with B-cell blood cancers and will determine whether the side effects re-emerge with Brukinsa.